廣告
香港股市 已收市
  • 恒指

    18,335.32
    -95.07 (-0.52%)
     
  • 國指

    6,556.10
    -31.67 (-0.48%)
     
  • 上證綜指

    3,005.44
    -12.61 (-0.42%)
     
  • 道指

    38,834.86
    +56.76 (+0.15%)
     
  • 標普 500

    5,487.03
    +13.80 (+0.25%)
     
  • 納指

    17,862.23
    +5.21 (+0.03%)
     
  • Vix指數

    12.59
    +0.11 (+0.88%)
     
  • 富時100

    8,225.98
    +20.87 (+0.25%)
     
  • 紐約期油

    81.59
    +0.02 (+0.02%)
     
  • 金價

    2,352.50
    +5.60 (+0.24%)
     
  • 美元

    7.8036
    -0.0026 (-0.03%)
     
  • 人民幣

    0.9298
    +0.0007 (+0.08%)
     
  • 日圓

    0.0490
    -0.0001 (-0.28%)
     
  • 歐元

    8.3681
    -0.0192 (-0.23%)
     
  • Bitcoin

    65,913.49
    +838.19 (+1.29%)
     
  • CMC Crypto 200

    1,376.02
    -6.64 (-0.48%)
     

The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.

The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.

Insmed stock catapulted Tuesday after the biotech company's experimental lung disease treatment succeeded in a final-phase study.